First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies
FAZ053 monotherapy was well tolerated and effective in maintaining disease control in various tumors including ASPS and chordoma. The anticipated synergistic effect of combined programmed cell death protein 1 (PD-1) and PD-L1 inhibition was not observed. These findings contribute to the growing evidence that rare, phenotypically 'immune cold' sarcomas, such as ASPS and chordoma, can become responsive to immune checkpoint inhibitors.
Authors
- Filip Janku
- Jennifer Mataraza (ORCID: https://orcid.org/0009-0004-5898-007X)
- A. Gucalp
- Sebastian Szpakowski (ORCID: https://orcid.org/0009-0000-5368-028X)
- Ralf D. Reiners (ORCID: https://orcid.org/0009-0005-9101-767X)
- S. Takahashi
- Philippe Lucien Bedard (ORCID: https://orcid.org/0000-0002-6771-2999)
- Ravit Geva (ORCID: https://orcid.org/0000-0002-5380-4948)
- Kartik Subramanian (ORCID: https://orcid.org/0000-0002-6900-8882)
- Xiaoling Chen (ORCID: https://orcid.org/0000-0002-2271-1140)
- Juan Martín-Liberal (ORCID: https://orcid.org/0000-0003-2552-5172)
- David S.P. Tan (ORCID: https://orcid.org/0000-0001-9087-5262)
- Ching‐Lung Lai (ORCID: https://orcid.org/0000-0002-5927-2436)
- R. Kan
- Albiruni Abdul Razak
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Tel Aviv Sourasky Medical Center (IL)
- Princess Margaret Cancer Centre (CA)
- Novartis (China) (CN)
- Novartis (United States) (US)
- The Cancer Institute Hospital (JP)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105051
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Karyopharm Therapeutics
- Novartis Pharmaceuticals Corporation
- Les Laboratories Pierre Fabre
- Iterion Therapeutics
- Daiichi-Sankyo
- Eisai
- Astellas Pharma
- Servier
- Ipsen
- Symphogen
- Genentech
- Chugai Pharmaceutical
- Daiichi Sankyo Europe